TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04168762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Ultrasound Magnetic Stimulation
Description: Transcranial Ultrasound Magnetic Stimulation is a paradigm that allows for concurrent and concentric ultrasound stimulation with transcranial magnetic stimulation (TMS).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Ultrasound Magnetic Stimulation
Description: Transcranial Ultrasound Magnetic Stimulation is a paradigm that allows for concurrent and concentric ultrasound stimulation with transcranial magnetic stimulation (TMS).
Study: NCT04110275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human tissue-type plasminogen activator derivative
Description: Recombinant human tissue-type plasminogen activator derivative(rPA,chemical name: Reteplase,brand name:Ruitongli) 18mg/10ml/stick, provided by AngDe Biotech Pharmaceutical Co.,LIMITED(LTD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human tissue-type plasminogen activator derivative
Description: Recombinant human tissue-type plasminogen activator derivative(rPA,chemical name: Reteplase,brand name:Ruitongli) 18mg/10ml/stick, provided by AngDe Biotech Pharmaceutical Co.,LIMITED(LTD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human tissue-type plasminogen activator
Description: Recombinant human tissue-type plasminogen activator(rt-PA,chemical name:Alteplase,brand name: Actilyse)50mg/stick,provided by Boehringer Ingelheim Pharma Gesellschaft mit beschrankter Haftung(GmbH)\&Co,
Study: NCT03689140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoke Free Together - App-only
Description: Pregnant smokers and their life partners will use a smoking cessation app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoke Free Together - Telemedicine counseling only
Description: Pregnant smokers and their life partners will use telemedicine, real time video counseling on smoking cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoke Free Together - app + telemedicine
Description: Pregnant smokers and their life partners will use telemedicine and an app for smoking cessation
Study: NCT04188223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis B (Bio Farma) Vaccine
Description: Recombinant Hepatitis B vaccine produced by Bio Farma

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Hepatitis B (Bio Farma) Vaccine®
Description: Registered Recombinant Hepatitis B vaccine produced by Bio Farma
Study: NCT03812146

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PC-TAU
Description: PC-TAU consists of Brief Advice intervention from their PC medical provider that is built into the electronic medical record as a mandatory response to a positive screen. In addition, patients who score positive on the AUDIT-C or PC-PTSD are offered a referral to the PCMHI provider within the PC clinic. PCMHI in VA consists of licensed, independent providers (typically psychologists or clinical social workers) providing brief assessment and interventions to veterans and consultation to other members of the PC team. PCMHI sessions are typically focused on assessment, psycho-education, and supportive counseling.
Study: NCT01176539

Intervention type: DEVICE
Intervention: Non-Contact Respiratory Rate Monitor
Description: The Non-Contact Respiratory Rate Monitor provides a measurement of respiratory rate at a single point in time for neonates, pediatrics and adults.~The Non-Contact Respiratory Rate Monitor provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults.
Study: NCT01713218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, week 1 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: 150 mg capsule, oral, once daily

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: Combination of gemcitabine and Vismodegib during a window interval (4 weeks) before surgery
Study: NCT00579917

Intervention type: BEHAVIORAL
Intervention: Cognitive Behavioral Therapy: Questionnaires
Description: CBT, we will interview you again after you have completed the 10 sessions. We call these follow-up interviews, and they include several phone calls and a questionnaire you would be asked to complete and then mail in. Each follow-up interview will take between 60 and 210 minutes. If you wish, these follow-up interviews can be done over different days. We will do the follow-up interviews three times; at approximately 4 months, 7 months, and 10 months after you complete the baseline interview.

Intervention type: BEHAVIORAL
Intervention: Usual Care: Questionnaires
Description: If you receive Usual Care, you will not receive CBT while you are in the study. You will complete the questionnaires at the same time as participants who receive CBT. If you receive Usual Care you will be offered 10 sessions of CBT at no charge at the end of the study.
Study: NCT00407992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occipital nerve stimulation ON
Description: Implant of an occipital nerve stimulator switched ON

Intervention type: DEVICE
Group type: OTHER
Intervention: Occipital nerve stimulation off
Description: Implant of an occipital nerve stimulator switched OFF
Study: NCT01054820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLECTORÂ® Patch (diclofenac epolamine topical patch) 1.3%
Description: One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.
Study: NCT04471818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
Study: NCT01914926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Study: NCT00328419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photoprotected bags, tubing, syringes
Description: use of photoprotected parenteral nutrition device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard tubing and bags
Description: Use of standard (transparent) parenteral nutrition device
Study: NCT03719105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Patients will receive methotrexate as part of chemoimmunotherapy regemin followed by allogeneic stem cell transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralatraxate,
Description: Patients will receive pralaxtraxate as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Patients will receive Ifsofamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients will receive dexamethasone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Patients will receive etoposide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calaspargase pegol
Description: Patients will receive pegaspargase as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Patients will receive cyclophosphamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Patients will receive doxorubicin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Patients will receive prednisone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Patients will receive brentuximab vedotin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
Study: NCT01716754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 was supplied as 120 mg liquid in vial per 1 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 was supplied as 120 mg liquid in vial per 1 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 was supplied as 120 mg liquid in vial per 1 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 was supplied as 120 mg liquid in vial per 1 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 was supplied as 120 mg liquid in vial per 1 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 was supplied as 120 mg liquid in vial per 1 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab was supplied as 150 mg lyophilisate in vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL
Study: NCT03877042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cruciate-retaining (CR) prostheses
Description: One leg is conducted TKA with Cruciate-retaining (CR) prostheses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior-stabilized (PS) prostheses
Description: One leg is conducted TKA with Posterior-stabilized (PS) prostheses.
Study: NCT02605954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablets administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC/3TC
Description: 600/300 mg tablets administered orally once daily
Study: NCT01988428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2000 mg
Description: Ceftriaxone 2000 mg
Study: NCT02605954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Third Antiretroviral Agent
Description: Third antiretroviral agents could include one of the following:~* ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC~* DRV+COBI or DRV/COBI FDC~* darunavir (DRV; Prezista®) + RTV~* lopinavir/ritonavir (LPV/r; Kaletra®)~* atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)~* efavirenz (EFV; Sustiva®)~* etravirine (ETR; Intelence®)~* nevirapine (NVP; Viramune®)~* rilpivirine (RPV; Edurant®)~* dolutegravir (DTG; Tivicay®)~* raltegravir (RAL; Isentress®)~* fosamprenavir (FPV; Lexiva®) + RTV~* saquinavir (SQV; Invirase®) + RTV~* ATV (no booster)~Drug classes:~* Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV and SQV~* Pharmacokinetic enhancer: COBI~* Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~* Integrase inhibitors: RAL and DTG
Study: NCT02590354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ART interruption
Study: NCT02327026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bag-valve-mask ventilation
Description: Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tracheal intubation
Description: Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management
Study: NCT02513160

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, taken in the morning and evening each day, was provided in matching BAI and MDI devices.~The placebo devices were identical to the devices used to deliver active drug.
Study: NCT03110289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: superdonor FMT
Description: Fecal microbiota transplantation (FMT) is the transfer of feces from a healthy superdonor to the patient.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: autologous FMT
Description: Fecal microbiota transplantation (FMT) with feces from the patient him/herself
Study: NCT01369342

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 1: Placebo
Description: Form=solution for injection, route=intravenous use, in a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2 ustekinumab 130 mg
Description: Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 3: ustekinumab approximately 6 mg/kg
Description: Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg), 390 mg (weight \> 55 kg and \<= 85 kg), and 520 mg (weight \> 85 kg).
Study: NCT00583726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: telephone counseling
Study: NCT03658278

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juven
Description: Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations
Study: NCT02513160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate via 320 mcg BAI
Description: Beclomethasone dipropionate treatment administered via breath-actuated inhaler (BAI) (320 mcg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: Each patient's current rescue medication was replaced with study-supplied albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent during the run-in and double-blind study periods.
Study: NCT01697397

Intervention type: DEVICE
Intervention: Recording of Myoelectric Signals
Description: Obtain recordings of the electrical signals of the gut.
Study: NCT02986152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Distress Coach Mobile App
Description: Cancer Distress Coach is a stand-alone symptom management tool with three basic components. The Learn about Distress module provides psycho-education. The Insights module includes an inspiring Quote of the Day, daily activity planning tips, a graph displaying the user's distress level plotted over time, and assessment feedback. The main action of the application is in the Activities module that provides patients with skills to manage their stress in the moment they experience it. Depending on the severity, the patient is routed to any of a number of helpful skills based on cognitive-behavioral principles. The stress management tools include positive imageries, soothing songs and pictures, and the Relax-Identify-Decide tool. Also included is find support and get support now to connect the user to his/her support network and locate informal cancer and non-cancer related support or (immediate) professional care.
Study: NCT00583726

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: written materials only
Description: dietary guidance materials and pedometers
Study: NCT02986152

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cancer Distress Coach Mobile App
Description: Cancer Distress Coach is a stand-alone symptom management tool with three basic components. The Learn about Distress module provides psycho-education. The Insights module includes an inspiring Quote of the Day, daily activity planning tips, a graph displaying the user's distress level plotted over time, and assessment feedback. The main action of the application is in the Activities module that provides patients with skills to manage their stress in the moment they experience it. Depending on the severity, the patient is routed to any of a number of helpful skills based on cognitive-behavioral principles. The stress management tools include positive imageries, soothing songs and pictures, and the Relax-Identify-Decide tool. Also included is find support and get support now to connect the user to his/her support network and locate informal cancer and non-cancer related support or (immediate) professional care.
Study: NCT03705169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR441236
Description: Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR441236
Description: Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
Study: NCT02513160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: Each patient's current rescue medication was replaced with study-supplied albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent during the run-in and double-blind study periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol/salbutamol
Description: Each patient's current rescue medication was replaced with study-supplied albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent during the run-in and double-blind study periods.
Study: NCT03705169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR441236
Description: Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR441236
Description: Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR441236
Description: Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
Study: NCT03821311

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed tomography
Description: End-inspiratory/end-expiratory CT is repeated 3 times corresponding to the 3 studied conditions: At baseline, through expiratory resistive loading using an adjustable PEP mask, and after 5 min of nasal high flow therapy at 25 L/min.
Study: NCT02513160

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albuterol/salbutamol
Description: Each patient's current rescue medication was replaced with study-supplied albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent during the run-in and double-blind study periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone dipropionate via 320 mcg MDI
Description: Beclomethasone dipropionate treatment administered via metered-dose inhaler (MDI) (320 mcg/day).
Study: NCT03972904

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Light-Fat Rice® combined with Active Peptide®+ lifestyle guidance
Description: Subjects will be given the Light-Fat Rice® combined with Active Peptide® with a lifestyle guidance to assist diabetes management. The method of taking the product has two parts: 1.Light-Fat Rice®: 80g (1 pack) per day as a staple meal replacement, used as a separate staple food or mixed with other staple foods, taking 4 weeks; 2.Active Peptide®: 20g (2 packs) per day (1 pack each morning and evening), served with 300ml of 40°C warm water each time before meals and take it for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin + lifestyle guidance
Description: A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin (both produced by the same manufacturer) with a lifestyle guidance will be given by the professional to assist in diabetes management. The product is taken as follows: 1.equal-energy staple food containing a small amount of dietary fiber: 80g (1 pack) per day, used as an independent staple food or mixed with other staple foods, taking for 4 weeks; 2.equal-energy maltodextrin: 20g(2 packs) per day(1 pack each morning and evening),take it with 300ml of 40°C warm water for 4 weeks.
Study: NCT04600765

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: hsCRP serum measurement of inflammation
Description: hsCRP inflammation change as result of non-contaminated diet
Study: NCT00607451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu-120
Description: Capsules of 300, 900 and 2700mg; administered as a single dose with a one week washout between each administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu-120
Description: Capsules of 300, 900 and 2700mg; administered as a single dose with a one week washout between each administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu-120
Description: Capsules of 300, 900 and 2700mg; administered as a single dose with a one week washout between each administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu-120
Description: Capsules of 300, 900 and 2700mg; administered as a single dose with a one week washout between each administration.
Study: NCT03497325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologus platelet rich plasma
Description: 55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision